Valuation: Dermapharm Holding SE

Market Cap 1.92B 2.16B 1.78B 1.61B 3.03B 204B 3.07B 21.34B 8.37B 107B 8.09B 7.92B 341B P/E 2026 *
14.8x
P/E 2027 * 13.1x
Enterprise Value 2.73B 3.07B 2.53B 2.29B 4.32B 290B 4.37B 30.35B 11.91B 152B 11.51B 11.27B 485B EV / Sales 2026 *
2.26x
EV / Sales 2027 * 2.08x
Free-Float
10.7%
Yield 2026 *
2.63%
Yield 2027 * 2.94%
1 day-0.19%
1 week+1.57%
Current month-1.15%
1 month-2.52%
3 months-3.85%
6 months-15.30%
Current year-1.52%
1 week 37.4
Extreme 37.4
39.05
1 month 37.35
Extreme 37.35
39.85
Current year 34.3
Extreme 34.3
51.9
1 year 32.4
Extreme 32.4
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 2017-07-31
Director of Finance/CFO - 2022-10-31
Investor Relations Contact - 2018-11-30
Director TitleAgeSince
Chairman 70 2017-07-31
Director/Board Member 66 2017-07-31
Director/Board Member 78 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Buy

Chairman

380,000 0.7670%
1/7/26 Buy 150 0.0003%
1/7/26 Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%+1.57%+17.42%+1.97% 2.16B
-1.01%+5.13%+58.93%+117.36% 1,133B
-0.61%+1.52%+34.34%+68.48% 621B
-1.48%+0.47%+23.08%+94.76% 503B
-0.54%+2.61%+38.89%+64.01% 379B
+1.07%+1.70%+71.06%+45.98% 370B
+0.62%+1.22%+21.53%+50.82% 292B
+0.03%-0.90%+0.35%+24.59% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 190B
Average -0.12%+2.96%+33.49%+62.26% 399.01B
Weighted average by Cap. +0.26%+3.73%+40.72%+79.66%

Financials

2026 *2027 *
Net sales 1.21B 1.36B 1.12B 1.01B 1.91B 128B 1.93B 13.42B 5.26B 67.27B 5.09B 4.98B 214B 1.25B 1.41B 1.16B 1.05B 1.98B 133B 2B 13.93B 5.46B 69.83B 5.28B 5.17B 223B
Net income 137M 154M 127M 115M 217M 14.53B 219M 1.52B 598M 7.64B 578M 566M 24.35B 155M 174M 144M 130M 245M 16.45B 248M 1.72B 677M 8.65B 654M 640M 27.55B
Net Debt 812M 911M 752M 680M 1.28B 85.96B 1.3B 9.01B 3.54B 45.18B 3.42B 3.35B 144B 687M 771M 636M 575M 1.08B 72.74B 1.1B 7.62B 2.99B 38.23B 2.89B 2.83B 122B
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
26-10-22 €38.75 -0.13% 1,403
26-10-21 €38.80 +1.44% 14,649
26-10-20 €38.25 +0.92% 11,373
26-10-19 €37.90 +0.13% 34,732
26-10-16 €37.85 -0.79% 14,600
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.80EUR
Average target price
51.00EUR
Spread / Average Target
+31.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE